Medicenna Therapeutics Corp.

As of June 30, 2026, Medicenna Therapeutics Corp. carries a market capitalization of 36.46M, placing it among publicly traded companies globally. Its enterprise value stands at 30.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medicenna Therapeutics Corp.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Medicenna Therapeutics Corp. has 92.30M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Medicenna Therapeutics Corp. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Medicenna Therapeutics Corp. posted a negative return on equity (ROE) of -227.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -119.69, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 19.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Medicenna Therapeutics Corp.'s stock has declined approximately 54.84% over the past 52 weeks. The 50-day moving average sits at 0.43, while the 200-day moving average is 0.57.

Over the twelve months ended June 30, 2026, Medicenna Therapeutics Corp. generated - - in revenue and converted that into -18.56M in net income, yielding earnings per share of -0.22. EBITDA reached -22.29M, while operating income came in at -22.36M.

As of June 30, 2026, Medicenna Therapeutics Corp. holds 5.69M in cash and equivalents against 104,000.00 in total debt, resulting in a net debt position of -5.69M. Total book value stands at 1.67M, with working capital of 1.64M providing operational flexibility.

Medicenna Therapeutics Corp. produced -18.81M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -18.81M - equivalent to -0.22 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -56.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.47, meaning Medicenna Therapeutics Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Medicenna Therapeutics Corp.'s most recent stock split took place on March 3, 2017 with a 14:1 split ratio.

As of June 30, 2026, Medicenna Therapeutics Corp. has an Altman Z-Score of -29.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.